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‘If I didn’t work on lupus, I would work on gout,’ I tell
my fellow as we stand outside the room of a patient with
an acute flare, his knee red and swollen. I have made this
assertion many times, eliciting surprise if not mystification
since lupus, the main focus of my research, and gout seem
polar opposites. Lupus is a chronic antibody-mediated dis-
ease while gout is an acute cytokine-mediated disease.
What I say next would prompt genuine concern about
my mental well-being. ‘And, if I worked on gout, I would
study the tophus,’ I say decisively.
Lest you think I am going off the rails, I believe that
study of the tophus holds important insights for immun-
ology. While interest in the tophus has surged recently
as an outcome measure in treatment, it is often an after-
thought, infrequently analyzed. Few studies have charac-
terized tophi by modern immunofluorescence or electron
microscopic techniques. Nevertheless, recent studies indi-
cate that the tophus may be a goldmine to find real gems
on immune regulation. Such studies are also strengthen-
ing what to me has always been quite simple and obvious:
the lupus–gout connection.
Despite differences in clinical course, both lupus and
gout concern the response to single molecules. These
molecules are linked biochemically and, indeed, one is
the product of the other. For lupus, the molecule is DNA;
for gout, it is uric acid. DNA is built of purines (and
pyrimidines), with uric acid a byproduct of purine degrad-
ation. Furthermore, both DNA and uric acid are damage-
associated molecular patterns, released during cell death
to signal danger and trigger inflammation. Hence, my at-
traction to these diseases.
It is in the context of immune regulation that the to-
phus takes center stage. Monosodium urate (MSU), the
crystalline salt form of uric acid, is one of the most pro-
inflammatory chemicals ever found. In the tophus core,
MSU should be present at enormous concentrations,
with milk of urate essentially a suspension of gout crys-
tals. Yet, despite the clear and present danger of soCorrespondence: david.pisetsky@dm.duke.edu
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the tophus is a remarkably placid structure. Even when
a tophus breaks down and milk of urate cascades out,
the result appears benign, the surrounding skin neither
red nor raw.
Even a novice investigator has to ask what is going on?
By analogy to Newton’s third law of motion, what is the
equal and positive reaction that pushes back on the gout
crystals’ action? As shown in a provocative study by
Schauer and colleagues in the journal Nature Medicine,
the neutrophil itself may perform the push back, pacify
the tophus and shut down a gout attack just as it fires
one up. This downregulatory mechanism involves an un-
expected player: the neutrophil extracellular trap (NET).
A NET is a mesh or web-like structure formed by the
mixture of chromatin with the contents of neutrophil
granules including antibacterial proteins such as myelo-
peroxidase, neutrophil elastase and cathelicidins. In a
process involving the generation of reactive oxygen spe-
cies by NAPH oxidase (Nox), the NET structure is
extruded into the extracellular space to kill bacteria or
fungi ensnared in this structure. Importantly, NETs are
present in the tophus.
Given its essential role in host defense, why should a
NET control inflammation? The intriguing studies by
Schauer and colleagues provide a neat explanation. Thus,
the proteases that stud the NET can also degrade cyto-
kines and hence curtail their action. With neutrophils
present in high concentrations, as could occur in gouty
inflammation, the NETs can aggregate to increase the
concentration of serine proteases to exert a counter-
regulatory action. Such aggregated NETs can degrade a
wide array of cytokines such as IL-6, MIP-1α, IL-1β and
TNF-α, all powerful players in gout pathogenesis. Since
NETs are present in the tophi, as shown by immuno-
fluorescence microscopy, they could represent a coun-
terforce that keeps the structure quiescent by degrading
cytokines, perhaps produced by macrophages.
An important set of experiments in the study by Schauer
and colleagues used murine models of gouty inflammation
in vivo. These studies involved ncf1++ mice, which are a
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oxygen species by Nox2 because of a mutation in neutro-
phil cytosolic factor 1 (encoded by Ncf1). In these studies,
administration of MSU crystals into air pouches of Ncf1++
mice led to higher levels of cytokines than those of wild-
type mice, while administration of MSU crystals into the
foot pads of these NETosis-deficient animals had a more
chronic course that lasted for weeks. Furthermore, in an
air pouch model in wild-type mice, DNase treatment re-
duced the NET aggregation and modulated cytokine
production. Together, these studies suggest that NETosis
and the aggregation of NETs can restrain inflammation or
promote resolution in gout by degrading proinflammatory
cytokines.
The role of NETs in shaping the microenvironment of
the tophus is intriguing but much work remains to be
done to validate this hypothesis. More histopathology is
definitely needed since the few recent studies on this
subject indicate a striking paucity of neutrophils in the
tophus; on the other hand, analysis of proteins in the to-
phus indicates the presence of myeloperoxidase and his-
tones, both NET constituents. Perhaps neutrophils only
transiently populate the tophus, lay down the NETs and
then disappear. While large datasets – whether genomic,
transcriptomic or proteomic – are the vogue, it is re-
freshing to see pathological studies – the demonstration
of NETs near the tophus core – producing such exciting
insights. These insights in turn lead to a reconceptuali-
zation of the NET – from Wild West desperado into the
sheriff bringing law and order.
While my heart remains wedded to lupus, I cannot
help but feel a strange pull emanating from the tophus.
As the great Jacques Cousteau said: ‘The Sea, once it
casts its spell, holds one in its net of wonder forever’. I
feel the same way about the tophus and I am afraid that
I too will be entranced by a wondrous place and become
trapped in an entangling net.
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